Get started
Author

Tjerk S.J. Opstal

Observed names: Opstal TSJ, Opstal, T.S.J., Opstal, Tjerk S.J., T J S Opstal, T S J Opstal, T. S. J. Opstal, T.S.J. Opstal, Tjerk Opstal, Tjerk S J Opstal, Tjerk S Opstal, Tjerk S. J Opstal, Tjerk S. J. Opstal
Observed institutions: Radboud University Nijmegen, Sir Charles Gairdner Hospital, Radboud University Medical Center, Noordwest Ziekenhuisgroep, Werkgroep Cardiologische centra Nederland, Amsterdam University Medical Centers, GenesisCare, Amsterdam Cardiovascular Sciences, University of Amsterdam
ORCID: 0000-0003-3654-0327
Observed ORCID: 0000-0003-3654-0327
OpenAlex ID: A5055633476
Colchicine in Patients with Chronic Coronary Disease
2020 · Stefan M. Nidorf, Aernoud T.L. Fiolet, et al. · New England Journal of Medicine · 2,285
PDF
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials
2021 · Aernoud T L Fiolet, Tjerk S J Opstal, et al. · European Heart Journal · 256
Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease
2020 · Tjerk S.J. Opstal, Renate M. Hoogeveen, et al. · Circulation · 149
PDF
The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics
2019 · Stefan M Nidorf, Aernoud T. L Fiolet, et al. · American Heart Journal · 109
PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers
2019 · Renate M. Hoogeveen, Tjerk S.J. Opstal, et al. · JACC. Cardiovascular imaging · 83
Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudy
2021 · Max J.M. Silvis, Aernoud T.L. Fiolet, et al. · Atherosclerosis · 68
Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials
2024 · Aernoud T.L. Fiolet, Michiel H.F. Poorthuis, et al. · EClinicalMedicine · 67
Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome
2021 · Tjerk S.J. Opstal, Aernoud T.L. Fiolet, et al. · Journal of the American College of Cardiology · 59
PDF
Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein
2020 · Aernoud T. L. Fiolet, Max J. M. Silvis, et al. · PLoS ONE · 53
PDF
Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trial
2022 · Tjerk S.J. Opstal, Stefan M. Nidorf, et al. · International Journal of Cardiology · 33
Myocardial blood flow and myocardial flow reserve values in 13N–ammonia myocardial perfusion PET/CT using a time-efficient protocol in patients without coronary artery disease
2018 · Opstal TSJ, Knol RJJ, et al. · European Journal of Hybrid Imaging · 31
PDF
An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk
2023 · N. Mohammadnia, T.S.J. Opstal, et al. · Clinical Therapeutics · 24
PDF
The Effect of Years-Long Exposure to Low-Dose Colchicine on Renal and Liver Function and Blood Creatine Kinase Levels: Safety Insights from the Low-Dose Colchicine 2 (LoDoCo2) Trial
2022 · Amber van Broekhoven, Niekbachsh Mohammadnia, et al. · Clinical Drug Investigation · 21
PDF
The Effect of Low‐Dose Colchicine on the Phenotype and Function of Neutrophils and Monocytes in Patients with Chronic Coronary Artery Disease: A Double‐Blind Randomized Placebo‐Controlled Cross‐Over Study
2024 · Helin Tercan, Amber van Broekhoven, et al. · Clinical Pharmacology & Therapeutics · 18
PDF
Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial
2025 · Aernoud T L Fiolet, Andrew Lin, et al. · Heart · 17
Colchicine and diabetes in patients with chronic coronary artery disease: insights from the LoDoCo2 randomized controlled trial
2023 · Niekbachsh Mohammadnia, Jan Los, et al. · Frontiers in Cardiovascular Medicine · 16
PDF
Effect of PCSK9 Inhibition on the Plasma Proteome: A SPIRE SubStudy
2023 · Jordan M. Kraaijenhof, Tjerk S.J. Opstal, et al. · Arteriosclerosis Thrombosis and Vascular Biology · 6
PDF
Targeting residual inflammatory risk in coronary disease: to catch a monkey by its tail
2021 · A. T. L. Fiolet, T. S. J. Opstal, et al. · Netherlands Heart Journal · 6
PDF
Invasive coronary imaging of inflammation to further characterize high-risk lesions: what options do we have?
2024 · Jonathan Los, Frans B. Mensink, et al. · Frontiers in Cardiovascular Medicine · 5
PDF
End-of-trial inflammatory biomarkers, lipid levels, creatine kinase and markers of renal and liver function in the LoDoCo2 trial
2022 · A Van Broekhoven, N Mohammadnia, et al. · European Heart Journal · 3
PDF
Consistent Efficacy of Colchicine Over Time in Patients With Recent Versus Remote Prior Acute Coronary Syndrome - a Lodoco2 Substudy
2021 · Tjerk Opstal, Aernoud T.L. Fiolet, et al. · Journal of the American College of Cardiology · 3
PDF
Letter to the editor: Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns
2021 · Aernoud T L Fiolet, Tjerk S J Opstal, et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 2
PDF
Immune checkpoint inhibitor-induced myocarditis with atrioventricular conduction abnormalities: a case report
2026 · A. Strijdhorst, T.S.J. Opstal, et al. · ESMO Gastrointestinal Oncology · 1
PDF
The effects of colchicine in patients with diabetes mellitus and chronic coronary artery disease: a post-hoc analysis of the LoDoCo2-trial
2022 · N Mohammadnia, J Los, et al. · European Heart Journal · 1
PDF
Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies Attenuate Arterial Wall Inflammation In Statin Intolerant Patients In Absence Of Crp Change
2019 · R. Hoogeveen, T.S.J. Opstal, et al. · Atherosclerosis · 1
Works count: 32
Citation count: 3,316
H-index: 16
I10-index: 16
Year
Topic
Type